3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
3
Neoplasms
2
Carcinoma, Squamous Cell
2
Urinary Bladder Neoplasms
1
Melanoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
pembrolizumab
13
Nivolumab
6
Docetaxel
6
cemiplimab
5
avelumab
5
atezolizumab
5
Trastuzumab
5
Carboplatin
4
durvalumab
3
Polymerase Chain Reaction
3
Magnetic Resonance Spectroscopy
3
Gene Expression Profiling
3
Gemcitabine
3
Fluorouracil
3
Cisplatin
3
Biopsy
3
zimberelimab
2
utomilumab
2
ulixertinib
2
tisotumab vedotin
2
pertuzumab
2
palbociclib
2
belinostat
2
amminedichloro(2-methylpyridine)platinum(II)
2
Tetrahydrouridine
2
Radiotherapy
2
Radiosurgery
2
Oxaliplatin
2
Nicotine
2
Ipilimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Tiragolumab
×
Head & Neck
×
Clear all
NCT05259319
2023-10-17
IMMUNOs-SBRT
Centre Georges Francois Leclerc
Phase 1
Unknown
92 enrolled